(“RenovoRx” or the “Company”) (Nasdaq: RNXT), is a clinical-stage biopharmaceutical company developing novel precision oncology therapies based on a local drug-delivery platform.
Recently, the Company announced the publication of pre-clinical studies supporting the efficacy and drug delivery mechanism of RenovoRx’s Trans-Arterial Micro-Perfusion (“TAMP“) therapy platform.
Understand I’ll stay out of the weeds, which is a risk on therapeutic info pieces. The facts are enough to convince investors to give RNXT consideration.
Corporate Presentation for those who can’t wait to the end.
Oncology=Science of Cancer. One can never have too much information about this scourge, which thankfully is responding positively- but still rising– to new therapies and those in the pipeline with the promise of further saved and extended lives.
The 10 deadliest cancers
Pancreatic cancer.
Liver cancer and intrahepatic bile duct cancer.
Esophageal cancer.
Lung cancer and bronchus cancer.
Acute myeloid leukemia.
Brain cancer and other nervous system cancer.
Stomach cancer.
Ovarian cancer.
In the case of RNXT let’s chat about the Company’s TAMP platform and, one of the deadliest of all cancers, Pancreatic. This type of cancer is the most advanced product development.
“Currently, most cancer patients with solid tumors receive chemotherapy intravenously, meaning it is introduced systemically into the entire body and causes well known adverse side effects. RenovoRx’s patented TAMP therapy platform is designed to bypass traditional systemic delivery methods and provide precise delivery to bathe the target solid tumor in chemotherapy. This precise delivery also creates the potential to minimize a therapy’s systemic toxicities” (PR MAY 21/24 ).
“TAMP has the potential to provide a valuable treatment option to patients who have been diagnosed with solid tumors that may be difficult-to-treat,” said Dr. Farsad. “The study shows a possible mechanism for how TAMP can increase local therapeutic tissue concentration in solid tumors that is independent from traditional catheter-directed therapy. We are awaiting final outcomes of the Phase III clinical trial, currently underway, to validate this benefit.”
Dr. Farsad adds, “This platform has the potential to extend across a variety of unmet needs for localized therapeutic drug delivery.”
While this may seem esoteric to the average investor, it really isn’t. RNXT has developed a delivery system that focuses therapies such as chemo directly to the tumour rather than ‘bathe’ the area. And apparently can be used for other ‘localised’ drug therapy. The TAMP system also limits or eliminates targeting non areas that have no need of therapy.
Here are the stages of the Company’s product development pipeline. Of equal interest is the granting RNXT’s FDA Orphan Drug Designation granted to RenovoGemTM in pancreatic and bile duct cancers. Over the last 10 years only 3 drugs have been approved for pancreatic cancer treatment. They increase toxicity and add two months on average to patient lifespan. RNXT feels its RenovoGEM doubles the added lifespan and markedly reduces toxicity. Let’s review Orphan Drug designation;
“A status given to certain drugs called orphan drugs, which show promise in the treatment, prevention, or diagnosis of orphan diseases. An orphan disease is a rare disease or condition that affects fewer than 200,000 people in the United States. Orphan diseases are often serious or life threatening. In 1983, the U.S. government passed a law, called the Orphan Drug Act, to give drug companies certain financial benefits for developing orphan drugs. This law is meant to help bring more drugs to patients with rare diseases”. (NCI)
RenovoGem received FDA Orphan Drug Designation for pancreatic cancer and bile duct cancer, which provides 7 years of market exclusivity upon NDA approval.
One final point to RNXT’s development and study of TIGer-Pac, which addresses the fact that pancreatic tumours have low blood supply. The study is evaluating trans-arterial delivery, a form of intra-arterial administration, of an FDA- approved chemotherapy, gemcitabine, to treat LAPC (Locally Advanced Pancreatic Cancer) patients.
following stereotactic body radiation therapy (SBRT). The study is comparing treatment of gemcitabine with TAMP versus systemic IV administration of gemcitabine and nab-paclitaxel.
The Bottom Line.
For those who don’t know how a toaster works, RNXT may seem daunting. For those who have or knows someone who is suffering or passed from pancreatic cancer or other types, the Company is extremely relevant. While RNXT looks to improve the lives of people with various serious cancers, the attack on pancreatic is the most compelling asset IMHO. A few extra months may seem short, but coupled with lower toxicity, represent a God-send to sufferers and their families. Arguably, as well, partnerships and acquisitions are alive and well in the pharmaceutical space.
Take a few minutes to learn about RenovoRx and its progress. One successful therapy a big Company (can) make.
